Please login to the form below

Not currently logged in
Email:
Password:

Hydra Biosciences and Pfizer sign global R&D novel ion-channel agreement

Hydra Biosciences signs a collaboration agreement with Pfizer Global R&D to develop TRPV3-antagonist products for pain

Hydra Biosciences has signed a collaboration agreement with Pfizer Global R&D to develop TRPV3-antagonist product candidates for pain.

Per the agreement, US-based Hydra will receive upfront and success-based development milestone payments of USD 195m for the first developed product launched and more for additional approved indications.

Pfizer will fund all R&D under the agreement and will receive exclusive access to Hydra's current TRPV3 patents as well as an exclusive license to commercialise any compound from the collaboration. Once the products are on the market, Pfizer will pay worldwide royalties to Hydra.

Recent research on Transient Receptor Potential (TRP) antagonists indicates that they may act as multimodal signal integrators. Since TRP channels are only distantly related to voltage gated channels and homology among TRP family members is quite low, it is anticipated that specific and selective modulators may be more readily identified in this family than in other ion channel groups, limiting the potential for off-target effects, which have proven problematic in other ion channel families, such as Vioxx (rofecoxib) and other COX-2 inhibitors.

30th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics